---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027779"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T05:23:51.659506+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q3 net loss widens to $103M; revenue drops 51%; milestones from GSK and Takeda

## Summary
- Revenue $15.8M (down 51% YoY from $32.4M); net loss $102.9M (vs $72.0M loss); diluted EPS -$0.96 (vs -$0.68).
- Cash and investments $494.5M vs $482.3M at Sept 30, 2022; total assets $795.9M.
- Earned $30M milestone from GSK for Phase 2b start of ARO-HSD (NASH); $40M from Takeda for first patient in Phase 3 REDWOOD of fazirsiran.
- Completed enrollment of PALISADE Phase 3 for ARO-APOC3; data readout expected Q2 2024.
- R&D Day: ARO-RAGE inhaled dose of 184mg achieved 90% mean knockdown; TRiM platform shows CNS and adipose delivery advances.

## SEC filing metadata
- accession: 0001628280-23-027779
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828023027779/0001628280-23-027779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828023027779/arwr-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027779
- JSON: https://secwatch.observer/filing/0001628280-23-027779.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027779.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.